The role of natural killer cells in immunity against multiple myeloma

Leukemia and Lymphoma

Volumn 53, Issue 9, 2012, Pages 1666-1676

  Godfrey, James ^a   Benson, Don M ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

immunotherapy; multiple myeloma; Natural killer cells

Indexed keywords

BORTEZOMIB; CD2 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; DEXAMETHASONE; ELOTUZUMAB; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 21 RECEPTOR; L SELECTIN; LENALIDOMIDE; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; POMALIDOMIDE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; THALIDOMIDE; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ALLOIMMUNITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD; CANCER PATIENT; CD4+ CD25+ T LYMPHOCYTE; CELL FUNCTION; CELL SURVIVAL; CYTOTOXICITY; DISEASE COURSE; DISEASE SURVEILLANCE; DOWN REGULATION; DRUG EFFECT; DRUG SAFETY; HLA MATCHING; IMMUNE RESPONSE; IMMUNITY; IN VITRO STUDY; INNATE IMMUNITY; LYMPHOCYTE COUNT; MULTIPLE MYELOMA; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR CELL;

EID: 84865021329     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.676175     Document Type: Review

References (142)

1. K yle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111:2962-2972.
2. L angren O, Kyle RA, Rajkumar SV. From myeloma precursor disease to multiple myeloma: New diagnostic concepts and opportunities for early intervention. Clin Cancer Res 2011;17:1243-1252.
3. K umar SK, Rajkukmar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-2520.
4. P ratt G, Goodyear O, Moss P. Immunodefi ciency and immunotherapy in multiple myeloma. Br J Haematol 2007;138:563-569.
5. C aligiuri MA. Human natural killer cells. Blood 2008;112:461-469.
6. H erberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactiving of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specifi city. Int J Cancer 1985:16; 216-229.
7. K iessling R, Klien E, Wigzell G. Natural killer cells in the mouse. I. Cytotoxic cells wiThspecifi city for mouse Moloney leukemia cells. Specifi city and distribution according to genotype. Eur J Immunol 1975:5;112-117.
8. V ivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011;331:44-49.
9. B ryceson YT, March ME, Ljunggren HG, et a l. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 2006;214:73-91.
10. F arag SS, Fehniger TA, Ruggeri L, et a l. Natural killer cell receptors: New biology and insights into the graft-versus-leukemia eff ect. Blood 2002;100:1935-1947.
11. Valiante NM, Uhrberg M, Shilling HG, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 1997;7:739-751.
12. P arham P. MHC class I molecules and KIRs in human history, healThand survival. Nat Rev Immunol 2005;5:201-214.
13. A nfossi N, Andre P, Guia S, et a l. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006;25:331-342.
14. V ivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science 2004;306:1517-1519.
15. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-729.
16. Bottino C, Castriconi R, Pende D, et al. Identifi cation of PVR (CD155) and Nectin-2 (Cd112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003;198:557-567.
17. Joyce MG, Tran P, Zhuravleva MA, et a l. Crystal structure of human natural cytotoxicity receptor NKp30 and identifi cation of its ligand binding site. Proc Natl Acad Sci USA 2011;108:6223-6228.
18. Mandelboim O, Lieberman N, Lev M, et al. Recognition of hemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001;409:1055-1059.
19. S myThMJ, Cretney E, Kelly JM, et al. Activation of NK cell cytotoxicity. Mol Immunol 2005;42:501-510.
20. Frohn C, Hoppner M, Schlenke P, et al. Anti-myeloma activity of natural killer lymphocytes. Br J Haematol 2002;119:660-664.
21. O sterborg A, Nilsson B, Bjorkholm M, et a l. Natural killer cell activity in monoclonal gammopathies: Relation to disease activity. Eur J Haematol 1990;45:153-157.
22. F amularo G, D'Ambrosio A, Quintieri F, et al. Natural killer cell frequency and function in patients wiThmonoclonal gammopathies. J Clin Lab Immunol 1992;37:99-109.
23. S awanobori M, Suzuki K, Nakagawa Y, et al. Natural killer cell frequency and serum cytokine levels in monoclonal gammopathies: Correlation of bone marrow granular lymphocytes to prognosis. Acta Haematol 1997;98:150-154.
24. Jurisic V, Srdic T, Konjevic G, et al. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med Oncol 2007;24:312-317.
25. G onzalez M, San Miguel JF, Gascon A, et a l. Increased expression of natural-killer-associated and activation antigens in multiple myeloma. Am J Hematol 1992;39:84-89.
26. De Rossi G, De Sanctis G, Bottari V, et al. Surface markers and cytotoxic activities of lymphocytes in monoclonal gammopathy of undetermined signifi cance and untreated multiple myeloma. Increased phytohemagglutinin-induced cellular cytotoxicity and inverted helper/suppressor cell ratio are features common to boThdiseases. Cancer Immunol Immunother 1987;25:133-136.
27. U chida A, Yagita M, Sugiyama H, et al. Strong natural killer (NK) cell activity in bone marrow of myeloma patients: Accelerated maturation of bone marrow NK cells and their interaction wiThother bone marrow cells. Int J Cancer 1984;35:375-381.
28. O gmundsdottir HM. Natural killer cell activity in patients wiThmultiple myeloma. Cancer Detect Prev 1988;12:133-143.
29. G arcia-Sanz R, Gonzalez M, Orfao A, et al. Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Br J Haematol 1996;93:81-88.
30. K ing MA, Radicchi-Mastroianni MA. Natural killer cells and CD56- T cells in the blood of multiple myeloma patients: Ananlysis by 4-colour fl ow cytometry. Cytometry 1996;26:121-124.
31. E ge H, Gertz MA, Markovic SN, et al. Prediction of survival using absolute lymphocyte count for newly diagnosed patients wiThmultiple myeloma: A retrospective study. Br J Haematol 2008;141:792-798.
32. L u ZY, Bataille R, Poubelle P, et a l. An interleukin-1 receptor antagonist blocks the IL-1 induced IL-6 paracrine production through a prostaglandin E2-related mechanism in multiple myeloma. Stem Cells 1995;13(Suppl. 2):28-34.
33. W ang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by STAT-3 signaling in tumor cells. Nat Med 2004;10:48-54.
34. K ortylewski M, Kujawski M, Wang T, et al. Inhibiting STAT3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005;11:1314-1321.
35. G hiringhelli F, Menard C, Terme M, et al. CD4- CD25- regulatory T cells inhibit natural killer cell functions in a transforming growThfactor-b-dependent manner. J Exp Med 2005;202:1075-1085.
36. B eyer M, Kochanek M, Giese T, et al. In vivo peripheral expansion of na ïve CD4- Cd25high FoxP-3- regulatory T cells in patients wiThmultiple myeloma. Blood 2006;107:3940-3949.
37. T rotta R, Col JD, Ciarlariello D, et al. TGF-beta utilizes SMAD3 to inhibit CD-16 mediated IFN-gamma production and antibodydependent cellular cytotoxicity in human NK cells. J Immunol 2008; 181:3784-3792.
38. Y u J, Wei M, Becknell B, et al. Pro- and anti-infl amatory cytokine signaling: Reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity 2006;24:575-590.
39. T anner J, Tosato G. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest 1991;88:239-247.
40. T ripp CS, Wolf SF, Unanue ER. Interleukin 12 and tumor necrosis factor a are costimulators of interferon gamma production by natural killer cells in severe combined immune defi ciency mice wiThlisteriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci USA 1993;90:3725-3729.
41. D'Andrea A, Aste-Amezaga, Valiante N, et al. Interleukin-10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993;178:1041-1048.
42. L adetto M, Vallet S, Trojan A, et al. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 2005;105:4784-4791.
43. C etin M, Buyukberber S, Demir M, et al. Overexpression of cyclooxygenase-2 in multiple myeloma: Association wiThreduced survival. Am J Hematol 2005;80:169-173.
44. H oang B, Zhu L, Shi Y, et al. Oncogenic RAS mutations in myeloma cells selectively induce COX-2 expression, which participates in enhanced adhesion to fi bronectin and chemoresistance. Blood 2006;107:4484-4490.
45. H olt D, Ma X, Kundu N, et al. Prostaglandin E2 (PGE 2 ) suppresses natural killer cell function primarily through the PGE 2 receptor EP4. Cancer Immunol Immunother 2001;60:1577-1586.
46. S tefanidakis M, Koivunen E. Cell-surface association between matrix metalloproteinases and integrins: Role of the complexes in leukocyte migration and cancer progression. Blood 2006;108:1441-1450.
47. P rabhala RH, Pelluru D, Fulciniti M, et a l. Elevated IL-17 produced by TH17 cells promotes myeloma cell growThand inhibits immune function in multiple myeloma. Blood 2010;115:5385-5392.
48. F eyler S, von Lilienfeld-Toal M, Jarmin S, et al. CD4- CD25- FoxP3- regulatory T cells are increased whilst CD3-CD4- CD8-alphabetaTCR- double negative T cells are decreased in the peripheral blood of patients wiThmultiple myeloma which correlates wiThdisease burden. Br J Haematol 2009;144:686-695.
49. Li L, Benson DM Jr, DeAngelis S, et al. A small molecule, LLL12, inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growThsuppressive activity in human multiple myeloma cells. Int J Cancer 2012;130:1459-1469.
50. Catlett-Falcone R, Londowski TH, Oshiro MM, et al. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-115.
51. Bedel R, Thiery-Vuillemin A, Grandclement C, et al. Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells. Cancer Res 2011;71:1615-1626.
52. Matsuzaki H, Kagimoto T, Oda T, et a l. Natural killer activity and antibody-dependent cell-mediated cytotoxicity in multiple myeloma. Jpn J Clin Oncol 1985;15:611-617.
53. Komiyama K, Crago SS, Itoh K, et al. Inhibition of natural killer cell activity by IgA. Cell Immunol 1986;101:143-155.
54. Gherman M, Manciulea M, Bancu AC, et al. Regulation of human natural cytotoxicity by IgG-I. Characterization of the structural site on monomeric IgG responsible for inhibiting natural killer cell activity. Int Immunol 1987;24:743-750.
55. Frassinito MA, Silvestris F, Caff orio P, et al. IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity. Int J Clin Lab Res 1997;27:48-54.
56. Mota G, Galatiuc C, Popescu I, et a l. IgA monoclonal and polyclonal proteins as regulatory factors of the NK cytotoxic activity. Rom J Virol 1999;50:17-31.
57. B enson DM Jr, Yu J, Becknell B, et a l. Stem cell factor and IL-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells. Blood 2009;113:2706-2714.
58. Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 2005;86:209-239.
59. Neilsen H, Neilsen HJ, Tyede N, et a l. Immune dysfunction in multiple myeloma. Reduced natural killer cell activity and increased levels of soluble interleukin-2 receptors. APMIS 1991;99:340-346.
60. C arson WE, Fehniger TA, Haldar S, et a l. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 1997;99:937-943.
61. K oka R, Burkett PR, Chien M, et al. Interleukin (IL)-15Ra defi cient natural killer cells survive in normal but not IL-15Ra-defi cient mice. J Exp Med 2003;197:977-984.
62. T inofer I, Marschitz I, Henn T, et a l. Expression of a functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 2000;95:610-618.
63. Dimartis A, Bernassola F, Savino R, et al. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Cancer Res 1996;56:4213-4218.
64. Billadeau D, Jelinek DF, Shah N, et al. Introduction of an activated N-ras oncogene alters the growThcharacteristics of the interleukin-6 depenednt myeloma cell line ANBL6. Cancer Res 1995;55:3640-3646.
65. E l-Sherbiny YM, Meade JL, Holmes TD, et a l. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer-cell mediating killing of myeloma cells. Cancer Res 2007;67:8444-8449.
66. J inushi M, Vanneman M, Munshi NC, et al. MHC class-Rfis1 chain-related protein A antibodies and shedding are associated wiThthe progression of multiple myeloma. Proc Natl Acad Sci USA 2008;105:1285-1290.
67. Carbone E, Neri P, Mesuraca M, et a l. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005;105:251-258.
68. Perez-Andres M, Almeida J, Martin-Ayuso M, et al. Clonal plasma cells from monoclonal gammopathy of undetermined signifi cance, multiple myeloma, and plasma cell leukemia show diff erent expression profi les of molecules involved in the interaction wiThthe immunological bone marrow microenvironment. Leukemia 2005;19:449-455.
69. Perez-Andres M, Almeida J, Martin-Ayuso M, et al. Soluble and membrane levels of molecules involved in the interaction between clonal lasma cells and the immunological microenvironment in multiple myeloma and their association wiThthe characteristics of the disease. Int J Cancer 2009;124:367-375.
70. Iwai Y, Ishida M, Tanaka Y, et a l. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99:12293-12297.
71. Benson DM Jr, Bakan CE, Mishra A, et a l. The PD-1/PD-L1 signaling axis modulates the natural killer cell versus multiple myeloma eff ect: A therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010;116:2286-2294.
72. Soriani A, Zingoni A, Cerboni C, et al. ATM-ATR-dependent upregulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated wiTha senescent phenotype. Blood 2009;113:3503-3511.
73. B ernal M, Garrido P, Jimenez P, et al. Changes in the activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: Implications for tumor evasion of T and NK cells. Hum Immunol 2009;70:854-857.
74. L andowski TH, Qu N, Buyuksal I, et a l. Mutations in the Fas antigen in patients wiThmultiple myeloma. Blood 1997;90:4266-4270.
75. v on Lilienfeld-Toal M, Frank S, Leyendecker C, et al. Reduced immune eff ector cell NKG2D expression and increase levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. Cancer Immunol Immunother 2010;59:829-839.
76. F auriat C, Mallet F, Olive D, et al. Impaired activating receptor expression pattern in natural killer cells from patients wiThmultiple myeloma. Leukemia 2006;20:732-733.
77. K irkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J Clin Oncol 1984;2:336-352.
78. E inhorn S, Ahre A, Blomgren H, et al. Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferoninduced enhancement of natural killer activity and clinical response to human interferon-alpha. Int J Cancer 1982;30:167-172.
79. M illar BC, Bell JB, Powles RL. Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy. Br J Cancer 1996;73:236-240.
80. H all PD, Self SE, Hall RK. The interaction of maintenance interferon wiThcytolytic cells in patients wiThmultiple myeloma who responded to cytotoxic chemotherapy. Pharmacotherapy 1997;17: 248-255.
81. G isslinger H. Interferon alpha in the therapy of multiple myeloma. Leukemia 1997;11(Suppl. 5):S52-S56.
82. F ritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: Meta-analysis of 30 randomized trials among 3948 patients. Ann Oncol 2000;11:1427-1436.
83. B rowman GP, Bergsagel D, Sicheri D, et al. Randomized trial of interferon maintenance in multiple myeloma: A study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1995;13:2354-2360.
84. A nderson KC, Alsina M, Bensinger W, et al. Multiple myeloma. J Natl Compr Canc Netw 2011;9:1146-1183.
85. B ianchi A, Omede P, Attisano C, et al. Phenotypic and functional analysis of peripheral blood lymphocytes during interferon-alpha 2b therapy in multiple myeloma patients wiThlow tumor mass. Haematologica 1991;76:383-388.
86. S himazaki C, Atzpodien J, Wisniewski D, et al. Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cells. Acta Haematol 1988;80:203-209.
87. G ottlieb DJ, Prentice HG, Heslop HE, et al. Eff ects of recombinant interleukin-2 administration on cytotoxic function following highdose chemo-radiotherapy for hematological malignancy. Blood 1989;74:2335-2342.
88. G ottlieb DJ, Prentice HG, Mehta AB, et al. Malignant plasma cells are sensitive to LAK cell lysis: Pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma. Br J Haematol 1990;75:499-505.
89. P orrata LF, Inwards DJ, Lacy MQ, et al. Immunomodulation of early engrafted natural killer cells wiThinterleukin-2 and interferonalpha in autologous stem cell transplantation. Bone Marrow Transplant 2001;28:673-680.
90. P eest D, Leo R, Deicher H. Tumor-directed cytotoxicity in multiple myeloma - the basis for an experimental treatment wiThinterleukin-2. Stem Cells 1995;13(Suppl. 2):72-76.
91. Higuchi CM, Thompson JA, Petersen FB, et a l. Toxicity andimmunomodulatory eff ects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991;77:2561-2568.
92. P orrata LF, Gertz MA, Inwards DJ, et a l. Early lymphocyte recoverypredicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma. Blood 2001;98:579-585.
93. P orrata LF, Gertz Ma, Geyer SM, et al. The dose of infused lymphocytes in the autograft directly correlates wiThclinicaloutcomes after autologous peripheral blood hematopoietic stem celltransplantation in multiple myeloma. Leukemia 2004;18:1085-1092.
94. K im H, Sohn HJ, Kim S, et al. Early lymphocyte recoverypredicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006;37:1037-1042.
95. H iwase DK, Hiwase S, Bailey M, et al. Higher infused lymphocytedose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2008;14:116-124.
96. P oratta LF, Gastineau DA, Padley D, et a l. Re-infused autologousgraft natural killer cells correlates wiThabsolute lymphocyte countrecovery after autologous stem cell transplantation. Leuk Lymphoma 2003;44:997-1000.
97. S iddiqui MA, Markovic SN, Nevala WK, et a l. Day 15 naturalkiller cell recovery predicts progression free survival after autologousstem cell transplantation in non-Hodgkin lymphoma. Blood 2006;108(Suppl. 1): Abstract 2914.
98. M arkasz L, Stuber G, Vanherberghen B, et al. Eff ect of frequentlyused chemotherapeutic drugs on the cytotoxic activity of human natural killer cells. Mol Cancer Ther 2007;6:644-654.
99. Gabriel IH, Sergeant R, Szydlo R, et a l. Interaction betweenKIR3DS1 and HLABw4 predicts for progression-free survival afterautologous stem cell transplantation in patients wiThmultiple myeloma. Blood 2010;116:2033-2039.
100. Lokhorst H, Einsele H, Vesole D, et a l. International myelomaworking group consensus statement regarding the current status of allogeneic stem cell transplantation for multiple myeloma. J Clin Oncol 2010;28:4521-4530.
101. Gharton G. Progress in allogeneic stem cell transplantation for multiple myeloma. Eur J Haematol 2010;85:279-289.
102. Tricot G, Vesole DH, Jagannath S, et al. Graft versus myeloma eff ect: Proof of principle. Blood 1996;87:73-91.
103. Alici E, Konstantinidis KV, Sutlu T, et al. Anti-myeloma activityof endogenous and adoptively transferred activated natural killercells in experimental multiple myeloma model. Exp Hematol 2007;35: 1839-1846.
104. Ruggeri L, Capanni M, Urbani E, et al. Eff ectiveness of donornatural killer cell alloreactivity in mismatched hematopoietictransplants. Science 2002;295:2097-2100.
105. Kroger N, Shaw B, Iacobelli S, et a l. Comparison betweenantithymocyte globulin and alemtuzumab and the possible impact ofKIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients wiThmultiple myeloma. Br J Haematol 2005;129:631-643.
106. Shi J, Tricot G, Szmania S, et al. Infusion of halpo-identical killerimmunoglobulin-like receptor ligand mismatched NK cells for relapsedmyeloma in the setting of autologous stem cell transplantation. Br JHaematol 2008;143:641-653.
107. Kroger N, Zabelina T, Berger J, et a l. Donor KIR haplotypeB improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia 2011;25:1657-1661.
108. Lioznov M, El-Cheikh J, Hoff mann F, et al. Lenalidomide assalvage therapy after allo-SCT for multiple myeloma is eff ective andleads to an increase in activated NK (NKp44-) and T (HLA-DR-) cells. Bone Marrow Transplant 2010;45:349-353.
109. Quach H, Ritchie D, Stewart AK, et a l. Mechanism of action ofimmunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia2001;24:22-32.
110. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-216.
111. H ayashi T, Hideshima T, Akiyama M, et a l. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: Clinicalapplication. Br J Haematol 2005;128:192-203.
112. Schafer PH, Gandhi AK, Loveland MA, et a l. Enhancementof cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003;305:1222-1232.
113. Tai YT, Li XF, Catley L, et a l. Immunomodulatory druglenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: Clinical implications. CancerRes 2005;65:11712-11720.
114. G orgun G, Calabrese E, Soydan E, et al. Immunomodulatoryeff ects of lenalidomide and pomalidomide on interaction of tumorand bone marrow accessory cells in multiple myeloma. Blood2010;116:3227-3237.
115. Benson DM Jr, Bakan CE, Zhang S, et al. IPH2101, a novel antiinhibitorKIR antibody, and lenalidomide combine to enhance thenatural killer cell versus multiple myeloma eff ect. Blood 2011;118:6387-6391.
116. Mitsiades CS. How immunomodulatory are IMIDs? Blood 2011;117:1440-1441.
117. G handhi AK, Kang J, Capone L, et al. Dexamethasone synergizeswiThlenalidomide to inhibit multiple myeloma tumor growth, butreduced lenalidomide-induced immunomodulation of T and NK cellfunction. Curr Cancer Drug Targets 2010;10:155-167.
118. H su AK, Quach H, Tai T, et a l. The immuno-stimulatory eff ect oflenalidomide on NK cell function is profoundly inhibited by concurrentdexamethasone therapy. Blood 2011;117:1605-1613.
119. S hi J, Tricot G, Garg TK, et a l. Bortezomib down-regulates thecell surface expression of HLA-class I and enhances natural killer cellmediated lysis of myeloma. Blood 2008;111:1309-1317.
120. W u X, Shao Y, Tao Y, et al. Proteasome inhibitor lacta cystinaugments natural killer cell cytotoxicity of myeloma via downregulationof HLA class I. Biochem Biophys Res Commun 2001;415:187-192.
121. H allett WH, Ames E, Motarjemi M, et a l. Sensitization of tumorcells to NK cell-mediated killing by proteasome inhibition. J Immunol 2008;180:163-170.
122. S tevenson FK, Bell AJ, Crusack R, et al. Preliminary studies foran immunotherapeutic approach to the treatment of human myelomausing chimeric anti-CD38 antibody. Blood 1991;77:1071-1079.
123. H si ED, Steinle R, Balasa B, et a l. CS1, a potential new therapeuticantibody target for the treatment of multiple myeloma. Clin Cancer Res 2008;14:2775-2784.
124. V an Rhee F, Szmania SM, Dillon M, et al. Combinatorial effi cacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63)and bortezomib against multiple myeloma. Mol Cancer Ther 2009;8:2616-2624.
125. C ruz-Munoz ME, Dong Z, Shi X, et a l. Infl uence of CRACC, aSLAM family receptor coupled to the adaptor EAT-2, on natural killercell function. Nat Immunol 2009;10:297-305.
126. C ollins SM, Bakan CE, Alghothani Y, et a l. The eff ect of elotuzumabon NK cell function against myeloma. J Clin Oncol 2011;29(15 Suppl.):Abstract 2572.
127. Z onder JA, Singhal S, Bensinger W, et a l. Phase I study ofelotuzumab (HuLuc63) in relapsed/refractory multiple myeloma.Blood 2011 Dec 19. [Epub ahead of print]
128. L onial S, Vij R, Harousseau J-L, et al. Elotuzumab in combinationwiThlenalidomide and low-dose dexamethasone in relapsed orrefractory multiple myeloma. J Clin Oncol 2011;29(15 Suppl.): Abstract8076.
129. J akubowiak AJ, Benson DM, Bensinger W, et a l. A phase I trialof anti-CS1 monoclonal antibody elotuzumab in combination withbortezomib in the treatment of relapsed/refractory multiple myeloma.J Clin Oncol 2012 Jan 30. [Epub ahead of print]
130. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plusdexamethasone for relapsed multiple myeloma in NorThAmerica.N Engl J Med 2007;357:2133-2142.
131. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plusdexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-2132.
132. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory multiple myeloma. N Engl J Med 2003;348:2609-2617.
133. Velardi A. Role of KIRs and KIR ligands in hematopoietic transplantation. Curr Opin Immunol 2008;20:581-587.
134. Romange F, Andre P, Spee P, et al. Preclinical characterization of 1 - 7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009;114:2667-2677.
135. B enson DM, Bakan C, Hofmeister CC, et al. Phase I trial of IPH2101 in patients wiThmyeloma. Haematologica 2011;96(Suppl.): Abstract P-194.
136. R ichardson PG, Lonial S, Jakubowiak AJ, et al. Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol 2011;154:745-754.
137. Atanackovic D, Panse J, Hildebrandt Y, et al. Surface molecule CD229 as a novel target for the diagnosis and treatment of multiplemyeloma. Haematologica 2011;96:1512-1520.
138. Zhu D, Corral LG, Fleming YW, et al. Immunomodulatorydrugs Revlimid (lenalidomide) and CC-4047 induce apoptosis ofboThhematological and solid tumor cells through NK cell activation. Canacer Immunol Immunother 2008;57:1849-1859.
139. Schmudde M, Braun A, Pende D, et al. Histone deacetylase inhibitors sensitive tumor cells for cytotoxic eff ects of natural killer cells. Cancer Lett 2008;272:110-121.
140. Fionda C, Soriani A, Malgarini G, et al. Heat shock protein- 90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. J Immunol 2009;183:4385-4394.
141. Alici E, Sutlu T, Bjorkstrand B, et a l. Autologous antitumoractivity by NK cells expanded from myeloma patients using GMPcompliantcomponents. Blood 2008;111:3155-3162.
142. Barkholt L, Alici E, Conrad R, et al. Safety analysis of ex vivo expanded NK and NK-like T cells administered to cancer patients: phase I clinical study. Immunotherapy 2009;1:753-764.